FDA accepts sNDA for Farxiga to reduce the risk of cardiovascular (CV) death or the worsening of heart failure . AstraZeneca
Related news and insights
High-level results from the DELIVER Phase III trial showed AstraZeneca’s Farxiga (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart failure (HF).
Nippon Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) has obtained a label update from PMDA in Japan allowing its use in patients with chronic heart failure with preserved ejection fraction (HFpEF) in addition to those with heart failure with reduced ejection fraction (HFrEF).